Background. In 68% of foodborne disease outbreaks, no etiologic pathogen is identified. In two-thirds of outbreaks with no identified etiology, no stool specimens are submitted for testing. Methods.
Geneoscopy’s New FDA-Approved Stool Collection Method Simplifies At-Home Colorectal Cancer Screening
ST. LOUIS, July 24, 2025--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, received FDA approval to ...
The US Food and Drug Administration (FDA) has approved an improved stool collection kit of Geneoscopy’s RNA-based colorectal cancer (CRC) screening test, ColoSense. The new kit enhances user ...
Among survey respondents with IBD who had used the mail-order option, 90.5% said they would recommend using a mail-order kit for future stool sample collection, and 83% said they would be interested ...
GeekWire chronicles the Pacific Northwest startup scene. Sign up for our weekly startup newsletter, and check out the GeekWire funding tracker and VC directory. by Charlotte Schubert on Jun 3, 2021 at ...
Fecal specimen collection in the clinical setting is often unfeasible for large population studies, especially because cancer patients on immunotherapy often experience constipation. A method for ...
Geneoscopy’s New FDA-Approved Stool Collection Method Simplifies At-Home Colorectal Cancer Screening
Pairing diagnostic innovation with improved patient experience, ColoSense aims to streamline the screening process and increase compliance Geneoscopy, Inc., a life sciences company focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback